What is mantle cell lymphoma?
Mantle cell lymphoma (MCL) is an uncommon type of B-cell non-Hodgkin lymphoma (NHL). It starts in B lymphocytes, the white blood cells that make antibodies, in the outer “mantle zone” of the lymphoid follicles inside lymph nodes.
MCL makes up only about 3-6 % of all non-Hodgkin lymphomas. It mostly affects older adults, and men are diagnosed two to three times more often than women.
Most people already have widespread disease when MCL is found. The lymph nodes, bone marrow, blood, spleen and bowel are often involved at the same time.
The behaviour of MCL varies a great deal. Some forms grow so slowly that they can be watched for years without treatment, while others are aggressive and need prompt, intensive therapy.
MCL is usually not curable with standard treatment, but outlook has improved markedly. Modern chemo-immunotherapy, maintenance treatment, BTK inhibitors and CAR T-cell therapy now give many patients long remissions, and many live well beyond ten years.
1. Epidemiology
| Feature | Detail |
|---|---|
| Incidence | Roughly 1 new case per 100,000 people per year in Western countries |
| Age at diagnosis | Median about 65-70 years; uncommon before 40 |
| Sex ratio | Male : female about 2-3 : 1 |
| Geography | Reported more often in North America and Europe than in Asia |
| Risk factors | No clear environmental or infectious cause; a family history of lymphoma slightly raises the risk |
The number of cases rises steeply with age. As populations grow older, MCL is expected to become somewhat more common.
2. Pathophysiology
2.1 Cell of origin
Most cases arise from mature B cells that have not passed through the germinal centre of the lymph follicle. These cells typically carry surface IgM and IgD.
In classic (nodal) MCL, the immunoglobulin heavy-chain genes (IGHV) are usually unmutated. A subset of cases, often the leukaemic non-nodal type, has mutated IGHV, showing that the cells have been exposed to the germinal-centre reaction.
2.2 The defining genetic change
The hallmark of MCL is the t(11;14)(q13;q32) translocation. It moves the CCND1 gene (which codes for cyclin D1) on chromosome 11 next to the immunoglobulin heavy-chain enhancer on chromosome 14.
The result is permanent over-production of cyclin D1. This protein pushes the cell from the resting G1 phase into the S phase of the cell cycle, so the lymphoma cells keep dividing.
2.3 Cyclin D1-negative MCL
A small minority of cases (a few per cent) do not express cyclin D1. Most of these are driven by rearrangements of CCND2, and less often CCND3, usually with immunoglobulin light-chain genes.
These tumours look and behave like typical MCL. They are recognised by the same overall pattern plus strong nuclear SOX11 staining, and the diagnosis can be supported by FISH testing for CCND2 rearrangement.
2.4 Additional molecular alterations
On top of cyclin D1, MCL cells collect further genetic hits that affect DNA repair, cell-cycle control and survival signalling.
| Gene / pathway | Approximate frequency | Significance |
|---|---|---|
| ATM (11q22-q23) | 40-50 % | Most frequently mutated gene; impairs the DNA-damage response |
| TP53 (mutation or 17p deletion) | 10-25 % | Strongly linked to chemoresistance and poor outcome |
| CDKN2A (p16INK4a) deletion | 15-25 % | Further deregulates the cell cycle; adverse prognosis |
| KMT2D | 10-20 % | Chromatin regulator; associated with shorter survival |
| NOTCH1 / NOTCH2 | 5-10 % | Activates NOTCH signalling; aggressive course |
| BIRC3 / TRAF2 | under 10 % | Activates alternative NF-kB signalling; may reduce response to ibrutinib |
| MYC rearrangement or gain | uncommon | Seen mainly in blastoid and pleomorphic disease |
These secondary changes help explain why MCL ranges from very slow-growing to highly aggressive disease.
2.5 Two clinical subtypes
The WHO classification recognises two main forms.
Classic (nodal) MCL is the common type. It is usually SOX11-positive, involves lymph nodes and other sites, and tends to need treatment soon after diagnosis.
Leukaemic non-nodal MCL is usually SOX11-negative with mutated IGHV. It mainly involves the blood, bone marrow and sometimes the spleen, with little or no lymph node enlargement, and often follows an indolent course. It can still become aggressive, especially when TP53 is altered.
3. How Does It Look?
3.1 What patients and doctors notice
On examination, the most visible sign is usually swollen lymph nodes in the neck, armpits or groin. They feel firm and rubbery and are usually painless.
An enlarged spleen may be felt under the left ribs. Swollen tonsils can be seen at the back of the throat, because MCL often involves Waldeyer’s ring.
During colonoscopy or gastroscopy, bowel involvement may appear as many small polyps lining the gut. This picture is called multiple lymphomatous polyposis and is typical of MCL.
3.2 Gross (macroscopic) appearance
| Site | Appearance |
|---|---|
| Lymph nodes | Enlarged, uniform, fleshy grey-white; necrosis uncommon (more in blastoid MCL). |
| Gut | Multiple polyps (lymphomatous polyposis) or thickened lining, from stomach to colon. |
| Spleen | Often enlarged with many small nodules. |
| Bone marrow | Involved in most patients. |
| Blood | Lymphoma cells often circulate. |
3.3 Microscopic (histologic) appearance
| Feature | Description |
|---|---|
| Growth pattern | Diffuse, vaguely nodular, or mantle-zone pattern around residual germinal centres |
| Cells | Monotonous small to medium-sized lymphocytes with irregular, notched (cleaved) nuclei |
| Chromatin and nucleoli | Fairly dispersed to condensed chromatin; nucleoli inconspicuous |
| Background | Scattered single pink epithelioid histiocytes and small hyalinised blood vessels; no large transformed cells (centroblasts) |
| Proliferation | Variable; Ki-67 under 30 % in most classic cases, often much higher in blastoid and pleomorphic disease |
| Immunophenotype | Positive: CD19, CD20, CD22, CD79a, FMC7, CD5 (most cases), cyclin D1 (nuclear), SOX11 (most classic cases). Usually negative: CD10, BCL6, CD23, CD200 |
| Genetics | t(11;14) shown by FISH or karyotype; CCND2 or CCND3 rearrangement in cyclin D1-negative cases |
3.4 Morphological variants
- Blastoid: cells resemble lymphoblasts, with fine chromatin and a high proliferation rate.
- Pleomorphic: larger, irregular cells, some with prominent nucleoli; can mimic diffuse large B-cell lymphoma.
- Small-cell and marginal zone-like: can be mistaken for chronic lymphocytic leukaemia or marginal zone lymphoma, which is why cyclin D1 and SOX11 staining matter.
Blastoid and pleomorphic variants behave aggressively and need more intensive treatment.
4. Symptoms
MCL can cause few or no symptoms early on. It is sometimes found by chance, for example on a routine blood count or on a scan done for another reason.
When symptoms appear, they depend on which parts of the body are involved. Some reflect the general effect of the lymphoma on the body.
4.1 B symptoms and general symptoms
About a third of patients have “B symptoms”, which doctors record because they reflect more active disease.
| Symptom | Typical presentation |
|---|---|
| Fever | Unexplained temperature above 38 °C, often recurring |
| Night sweats | Drenching sweats that soak night clothes or bedding |
| Weight loss | Unintentional loss of more than 10 % of body weight within 6 months |
| Fatigue | Persistent tiredness; common, but not counted as a B symptom |
4.2 Symptoms by site
| Site | Possible symptoms |
|---|---|
| Lymph nodes | Painless lumps in the neck, armpit or groin |
| Gastrointestinal tract | Abdominal pain, diarrhoea, bleeding, anaemia from blood loss, feeling full quickly |
| Bone marrow | Low blood counts causing tiredness, pallor, easy bruising or frequent infections |
| Spleen | Fullness or discomfort under the left ribs; early satiety |
| Waldeyer’s ring (tonsils, back of the throat) | Sore throat, difficulty swallowing, feeling of a lump in the throat |
| Blood (leukaemic phase) | Raised white cell count; may cause no symptoms |
| Skin, eyes, lungs (uncommon) | Nodules, swelling around the eye, cough or breathlessness |
| Brain and spinal cord (rare) | Headache, confusion, weakness or seizures, mainly in blastoid or relapsed disease |
4.3 Immune-related problems
- Autoimmune haemolytic anaemia and immune thrombocytopenia occur occasionally.
- Low antibody levels (hypogammaglobulinaemia) increase the risk of infections, particularly of the sinuses and lungs.
5. Staging and Prognosis
5.1 Staging (Lugano classification)
Lymphomas are staged with the Lugano classification (2014), which is based on the older Ann Arbor system.
| Stage | Definition |
|---|---|
| I | One lymph node or a group of adjacent nodes, or a single extranodal lesion without nodal disease (IE) |
| II | Two or more nodal groups on the same side of the diaphragm, with or without limited contiguous extranodal spread (IIE) |
| III | Lymph nodes on both sides of the diaphragm, or nodes above the diaphragm plus the spleen |
| IV | Additional non-contiguous extranodal involvement, for example bone marrow, liver, lung or bowel |
B symptoms do not change the stage number. In the Ann Arbor system they add the suffix “B” (for example stage IIIB), and doctors record them in MCL because they signal more active disease.
In the older Ann Arbor system, spleen involvement was marked with the suffix “S” (IIIS). In the Lugano system the spleen counts as nodal tissue.
Most patients have stage III or IV disease at diagnosis, mostly because of bone marrow and blood involvement. Truly limited stage I-II disease is uncommon.
5.2 The MIPI score
The Mantle Cell Lymphoma International Prognostic Index (MIPI) was developed by Hoster and colleagues in 2008. It uses four simple measurements taken at diagnosis:
- Age
- Performance status (ECOG)
- Blood LDH level compared with the upper limit of normal
- White blood cell count
The original MIPI combines these in a weighted formula that sorts patients into low, intermediate and high risk. In everyday practice, most doctors use the simplified MIPI, a points table:
| Points | Age (years) | ECOG | LDH / upper limit of normal | White cell count (x10⁹/L) |
|---|---|---|---|---|
| 0 | under 50 | 0-1 | under 0.67 | under 6.7 |
| 1 | 50-59 | – | 0.67-0.99 | 6.7-9.99 |
| 2 | 60-69 | 2-4 | 1.00-1.49 | 10.0-14.99 |
| 3 | 70 or over | – | 1.50 or more | 15.0 or more |
| Total score (0-11) | Risk group |
|---|---|
| 0-3 | Low risk |
| 4-5 | Intermediate risk |
| 6-11 | High risk |
Survival differs clearly between the three groups, with the high-risk group doing worst. The absolute numbers from the original studies predate modern treatment and are better now.
Adding the Ki-67 proliferation index gives the MIPI-c (combined MIPI), which separates risk groups even more sharply.
5.3 Other prognostic markers
| Marker | What it means |
|---|---|
| TP53 mutation or 17p deletion | Poor response to chemotherapy and shorter remissions; affects treatment choice |
| Ki-67 of 30 % or more | Fast-growing disease and higher risk |
| Blastoid or pleomorphic morphology | Aggressive behaviour; more intensive treatment usually needed |
| Leukaemic non-nodal, SOX11-negative disease | Often indolent; may be safely watched for a time |
| Minimal residual disease (MRD) | MRD-negative status after treatment predicts longer remission |
| Early relapse (within 24 months) | Signals aggressive biology and poor prognosis |
6. Diagnosis
| Step | Purpose | Typical tests |
|---|---|---|
| History and examination | Identify B symptoms, enlarged nodes, liver or spleen | Physical examination |
| Blood tests | Blood counts, organ function, prognosis | Full blood count, blood film, kidney and liver tests, LDH, uric acid, beta-2 microglobulin |
| Infection screening | Required before rituximab and other immune therapies | Hepatitis B and C, HIV |
| Biopsy | Confirm the diagnosis | Excisional lymph node biopsy preferred; core needle biopsy if excision is not possible |
| Immunophenotyping | Confirm the MCL pattern | Immunohistochemistry (cyclin D1, SOX11, CD5, Ki-67) and flow cytometry |
| Genetic tests | Confirm t(11;14) and look for high-risk changes | FISH for t(11;14); TP53 testing by sequencing or immunohistochemistry |
| Imaging | Stage the disease | PET-CT (preferred) or CT of neck, chest, abdomen and pelvis |
| Bone marrow biopsy | Show marrow involvement | Aspirate and trephine biopsy with flow cytometry |
| Endoscopy | Assess the bowel | Upper endoscopy and colonoscopy, especially when limited-stage disease is suspected or there are bowel symptoms |
| Lumbar puncture | Look for spread to the brain and spinal fluid | Considered in blastoid disease or with neurological symptoms |
A typical pathway is a lymph node biopsy, then staining for cyclin D1 and SOX11, then FISH for t(11;14). If cyclin D1 is negative but SOX11 is positive, the pathologist looks for a CCND2 or CCND3 rearrangement.
7. Treatment
Treatment depends on the patient’s age and fitness, the stage and speed of the disease, and high-risk features such as TP53 changes or blastoid morphology. Patient preference also plays an important role.
7.1 Watch and wait
Some patients, mainly those with leukaemic non-nodal MCL, a low Ki-67 and no symptoms, can be monitored without treatment at first.
Careful follow-up continues, and treatment starts when symptoms appear or the disease progresses. Delaying treatment in this group does not appear to harm survival.
7.2 Limited-stage disease
For the uncommon patient with true stage I or II disease without bulky masses, radiotherapy, sometimes combined with a shortened course of chemo-immunotherapy, can give long-lasting control.
7.3 Younger, fit patients
Younger patients (usually up to about 65-70 years) without major health problems receive intensive first-line treatment. The aim is the deepest and longest possible remission.
| Approach | Components | Notes |
|---|---|---|
| Cytarabine-containing induction | Alternating R-CHOP and R-DHAP (or a similar platinum-containing regimen); Nordic regimen with R-maxi-CHOP and high-dose cytarabine | Standard backbone in Europe; adding high-dose cytarabine improves results |
| R-HyperCVAD/MA | Cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with high-dose methotrexate and cytarabine, plus rituximab | Intensive; used mainly in the United States; significant toxicity |
| Ibrutinib added to induction and maintenance | Ibrutinib with induction, then about 2 years of ibrutinib maintenance | TRIANGLE trial: better outcomes than standard treatment with transplant |
| Autologous stem cell transplant (ASCT) | High-dose chemotherapy (often BEAM) with stem cell rescue | Long a standard consolidation; its role is being re-examined since TRIANGLE |
| Rituximab maintenance | Every 2 months for 3 years after ASCT | Prolongs remission and improves survival (LyMa trial) |
The TRIANGLE trial, published in 2024, showed that adding ibrutinib to standard induction and maintenance improved failure-free survival. Many experts now consider ibrutinib-containing treatment a new standard for younger patients.
TRIANGLE also tested ibrutinib-containing treatment without a transplant. As follow-up matures, more patients may be able to avoid ASCT, especially those without TP53 alterations.
7.4 Older or less fit patients
| Regimen | Key points |
|---|---|
| Bendamustine + rituximab (BR) | Widely used; well tolerated by most older patients |
| Acalabrutinib + BR | ECHO trial: longer progression-free survival than BR alone; FDA-approved in January 2025 for untreated MCL in adults ineligible for transplant |
| Ibrutinib + BR | SHINE trial: longer progression-free survival, but no overall survival benefit and more side effects |
| R-CHOP followed by rituximab maintenance | Rituximab maintenance after R-CHOP improves outcomes in older patients |
| VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone) | Bortezomib replaces vincristine; better progression-free and overall survival than R-CHOP; FDA-approved for untreated MCL |
| Lenalidomide + rituximab | Chemotherapy-free option for some frail patients |
In the ECHO trial, which enrolled patients aged 65 and over, the median progression-free survival was about 66 months with acalabrutinib plus BR, compared with about 50 months with BR alone.
7.5 Relapsed or refractory disease
Most patients eventually relapse, but there are now many effective options. The choice depends on what the patient received before, how long the remission lasted and the patient’s fitness.
| Treatment class | Examples | Notes |
|---|---|---|
| Covalent BTK inhibitors | Ibrutinib, acalabrutinib, zanubrutinib | Block B-cell receptor signalling; oral tablets taken continuously. Acalabrutinib and zanubrutinib are more selective, with fewer heart side effects |
| Non-covalent BTK inhibitor | Pirtobrutinib | Works after failure of covalent BTK inhibitors, including with C481 resistance mutations; US approval 2023 |
| CAR T-cell therapy | Brexucabtagene autoleucel; lisocabtagene maraleucel | Patient’s own T cells engineered to attack CD19; brexucabtagene autoleucel was FDA-approved in July 2020 based on ZUMA-2 |
| Bispecific antibodies | Glofitamab; others in trials | Redirect T cells against CD20; glofitamab has shown high response rates in heavily pre-treated MCL, including after BTK inhibitors |
| BCL-2 inhibitor | Venetoclax | Active in MCL; in combination with ibrutinib it improved progression-free survival in the SYMPATICO trial |
| Immunomodulatory drug | Lenalidomide, often with rituximab | Oral; useful after earlier treatments |
| Proteasome inhibitor | Bortezomib | Approved for relapsed MCL; now used less often |
| Chemo-immunotherapy | BR or cytarabine-based regimens | An option if the first remission was long |
| Allogeneic stem cell transplant | Donor stem cells | Potentially curative for a few fit patients, at the cost of significant risks |
Ibrutinib was the first BTK inhibitor approved for relapsed MCL, in 2013. Its accelerated US approval for MCL was withdrawn in 2023, but it remains in use in other countries and in combinations studied in trials.
In ZUMA-2, about 93 % of patients with relapsed MCL responded to brexucabtagene autoleucel, and about two thirds had a complete response. Many of these responses have lasted for years.
Patients who relapse after a BTK inhibitor are typically offered CAR T-cell therapy, pirtobrutinib, a bispecific antibody, venetoclax-based treatment or a clinical trial. Outcomes in this setting have improved considerably.
7.6 Maintenance
- Rituximab maintenance after ASCT in younger patients, and after R-CHOP in older patients, prolongs remission.
- Ibrutinib maintenance after induction is part of the TRIANGLE approach for younger patients.
- Lenalidomide maintenance after ASCT improved progression-free survival in one randomised trial but is not widely used.
7.7 Supportive care
| Issue | Measures |
|---|---|
| Low neutrophil count | G-CSF (filgrastim or pegfilgrastim) during chemotherapy |
| Infection prevention | Antiviral prophylaxis for hepatitis B carriers on rituximab; prophylaxis against herpes and Pneumocystis with certain regimens |
| Nerve damage | Linked mainly to bortezomib and vincristine; dose changes and pain medicines |
| Atrial fibrillation and high blood pressure | Linked mainly to ibrutinib; heart monitoring, standard treatment, or switching to a more selective BTK inhibitor |
| Bleeding risk | BTK inhibitors affect platelets; avoid unnecessary blood thinners and pause the drug around surgery |
| Tumour lysis syndrome | Hydration and allopurinol or rasburicase, especially with high tumour burden or venetoclax |
| CAR T-cell side effects | Monitoring for cytokine release syndrome and neurological toxicity in a specialist centre |
| Vaccinations | Inactivated influenza, pneumococcal and COVID-19 vaccines; avoid live vaccines during and after immune-suppressing treatment |
8. Living with Mantle Cell Lymphoma
8.1 Emotional and practical aspects
Living with a lymphoma that tends to come back can cause anxiety and uncertainty. Counselling and patient organisations such as the Lymphoma Research Foundation and Lymphoma Action offer information and support.
Many patients keep working, sometimes with reduced hours during intensive treatment. Help with sick leave, benefits and travel insurance is often available through hospital social workers.
Some treatments affect fertility. Younger patients should discuss sperm banking or egg freezing before treatment starts.
8.2 Monitoring and follow-up
| Time point | What happens |
|---|---|
| During treatment | Regular blood tests and symptom review; scans partway through induction |
| End of induction | Examination, blood tests and PET-CT, scored with the Deauville five-point scale |
| Maintenance | Clinic visits every 2-3 months with blood tests |
| After treatment | Visits every 3 months for 2 years, then every 6 months for 3 years, then yearly; scans mainly if symptoms or results suggest relapse |
| Long term | Checks for second cancers (including skin cancer), heart health, blood pressure and bone health |
Minimal residual disease (MRD) testing looks for tiny amounts of lymphoma DNA in the blood or bone marrow. It can show whether a remission is deep and may in future guide how long treatment lasts.
8.3 Lifestyle
- Exercise: about 150 minutes of moderate activity per week helps with fatigue and heart health.
- Nutrition: a balanced diet with fruit, vegetables and lean protein; limit alcohol.
- Infection avoidance: good hand hygiene and up-to-date vaccinations, especially when blood counts are low.
- Sun protection: important because the risk of skin cancer is increased.
9. Frequently Asked Questions
| Question | Short answer |
|---|---|
| Is mantle cell lymphoma curable? | Usually not with standard treatment, but many patients have remissions lasting years. Allogeneic transplant and CAR T-cell therapy can give very long-term control in some. |
| Can MCL become more aggressive? | Yes. Some cases become blastoid or pleomorphic, often with TP53 changes and a high Ki-67, and then need more intensive treatment. |
| How is MCL different from chronic lymphocytic leukaemia (CLL)? | Both are CD5-positive B-cell cancers. MCL is cyclin D1-positive and SOX11-positive and usually CD23- and CD200-negative, whereas CLL is CD23- and CD200-positive and cyclin D1-negative. |
| Will I need a stem cell transplant? | ASCT has long been standard for fit younger patients. Since the TRIANGLE trial, ibrutinib-based treatment may allow some to avoid it. Older patients are treated without transplant. |
| Are tablets as effective as chemotherapy? | Oral BTK inhibitors are highly effective in relapsed MCL and are now combined with chemo-immunotherapy in first-line treatment. Their side effects differ from those of chemotherapy. |
| What do new lumps or tiredness mean? | New swollen nodes, falling blood counts or returning B symptoms can signal relapse. They are usually checked with blood tests, scans and sometimes a new biopsy. |
10. Key Points
- Mantle cell lymphoma is a CD5-positive, cyclin D1-positive B-cell lymphoma defined by the t(11;14) translocation.
- It mainly affects older men and is usually widespread at diagnosis, often involving the bone marrow, blood and bowel.
- Under the microscope it shows small to medium-sized cells with irregular nuclei; cyclin D1 and SOX11 staining confirm the diagnosis.
- Staging follows the Lugano classification; the MIPI score, Ki-67 and TP53 status guide prognosis and treatment.
- Younger fit patients receive cytarabine-containing chemo-immunotherapy, increasingly with ibrutinib, followed by maintenance; the role of transplant is being redefined.
- Older patients are treated with BR (now often with acalabrutinib), VR-CAP or R-CHOP followed by rituximab maintenance.
- Relapsed disease has many options: BTK inhibitors, CAR T-cell therapy, bispecific antibodies, venetoclax and lenalidomide.
- Research focuses on chemotherapy-free combinations, MRD-guided treatment and better options for TP53-mutated disease.
Resources
- Alaggio, R. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms’, Leukemia, 36(7), pp. 1720-1748.
- Swerdlow, S.H. et al. (2016) ‘The 2016 revision of the World Health Organization classification of lymphoid neoplasms’, Blood, 127(20), pp. 2375-2390.
- Hoster, E. et al. (2008) ‘A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma’, Blood, 111(2), pp. 558-565.
- Jain, P. and Wang, M.L. (2022) ‘Mantle cell lymphoma in 2022 – A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments’, American Journal of Hematology, 97(5), pp. 638-656.
- Wang, M. et al. (2020) ‘KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma’, New England Journal of Medicine, 382(14), pp. 1331-1342.
- Dreyling, M. et al. (2024) ‘Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network’, The Lancet, 403(10441), pp. 2293-2306.
- Wang, M. et al. (2025) ‘Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma’, Journal of Clinical Oncology, 43(20), pp. 2276-2284.
- National Cancer Institute (2026) Mantle Cell Lymphoma Treatment (PDQ®) – Health Professional Version. Available at: https://www.cancer.gov/types/lymphoma/hp/mantle-cell-lymphoma-treatment (Accessed: October 2026).
- American Cancer Society (2026) Types of B-cell Lymphoma. Available at: https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/about/b-cell-lymphoma.html (Accessed: October 2026).
- Lymphoma Action (2026) Mantle cell lymphoma. Available at: https://lymphoma-action.org.uk/information-and-support/types-lymphoma/non-hodgkin-lymphoma/mantle-cell-lymphoma (Accessed: October 2026).
Prepared by the editorial team, October 2026.